Cargando…
Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2...
Autores principales: | Silva-Oliveira, Rita, Pereira, Filipa Ferreira, Petronilho, Sara, Martins, Ana Teresa, Lameirinhas, Ana, Constâncio, Vera, Caldas-Ribeiro, Inês, Salta, Sofia, Lopes, Paula, Antunes, Luís, Castro, Fernando, de Sousa, Susana Palma, Henrique, Rui, Jerónimo, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761245/ https://www.ncbi.nlm.nih.gov/pubmed/33276477 http://dx.doi.org/10.3390/jcm9123911 |
Ejemplares similares
-
Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence
por: Fontes-Sousa, Mário, et al.
Publicado: (2020) -
A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA
por: Salta, Sofia, et al.
Publicado: (2018) -
Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer
por: Amorim, Maria, et al.
Publicado: (2019) -
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2018) -
The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma
por: Lameirinhas, Ana, et al.
Publicado: (2019)